Abstract: A substrate processing apparatus includes a device management controller including a parts management control part configured to monitor the state of parts constituting the apparatus, a device state monitoring control part configured to monitor integrity of device data obtained from an operation state of the parts constituting the apparatus, and a data matching control part configured to monitor facility data provided from a factory facility to the apparatus. The device management controller is configured to derive information evaluating the operation state of the apparatus based on a plurality of monitoring result data selected from a group consisting of maintenance timing monitoring result data acquired by the parts management control part, device state monitoring result data acquired by the device state monitoring control part, and utility monitoring result data acquired by the data matching control part.

Abstract: To provide a compound having an inhibitory activity for an androgen receptor. A fused pyrimidine compound represented by the following formula (I) or a pharmaceutically acceptable thereof (in the formula, X, Y, Z, R1, and R2 are as defined in the specification).

Abstract: A method for inhibiting androgen activity, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof, and a method for treating tumor, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof

Abstract: To provide a compound having an inhibitory activity for an androgen receptor. A fused pyrimidine compound represented by the following formula (I) or a pharmaceutically acceptable thereof (in the formula, X, Y, Z, R1, and R2 are as defined in the specification).

Abstract: A method for inhibiting androgen activity, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof, and a method for treating tumor, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof

Abstract: A method for inhibiting androgen activity, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof, and a method for treating tumor, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof

Abstract: A tetrahydropyridopyrimidine compound represented by formula (I) or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition including the tetrahydropyridopyrimidine compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier:

Abstract: An image forming apparatus includes a controller for forming an adjustment toner image in a region corresponding to between a first region corresponding to a preceding sheet and a second region corresponding to a subsequent sheet, wherein the controller selectively executes a first mode for setting as a first length a gap between the adjustment image and a trailing edge of the first region and for setting as a second length a gap between the adjustment toner image and a leading end of the second region, or a second mode for setting as a third length a gap between the adjustment toner image and the trailing edge of the first region and for setting as a fourth length a gap between the adjustment image and the leading end of the second region. The third is shorter than the first, and the fourth length is longer than the first length.

Abstract: An image forming apparatus including a cleaning member having a belt cleaning blade and a conductive brush. A value of a charging current that is generated when charging residual toner with the conductive brush is smaller when a color mode is executed compared to that when a monochrome mode is executed.

Abstract: In an adjustment step, an adjustment purpose toner image is formed on an intermediate transfer belt, and the adjustment purpose toner image is removed from the intermediate transfer belt by a cleaning member contacting the intermediate transfer belt and through an electrostatic cleaning step. This adjustment step is executed in a state where a toner attachment amount on a charging member is switched from a first limit value, which is allowed in the image forming step to a second limit value, which is allowed immediately before executing the adjustment step. This switching is performed by the execution of a toner discharging step, where a power supply changes the state of applying voltage to the charging member from that in the electrostatic cleaning step, so that toner attached to the charging member is transferred to the intermediate transfer belt.

Abstract: A method for inhibiting androgen activity, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof, and a method for treating tumor, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof

Abstract: An image forming apparatus including a cleaning member having a belt cleaning blade and a conductive brush. A value of a charging current that is generated when charging residual toner with the conductive brush is smaller when a color mode is executed compared to that when a monochrome mode is executed.

Abstract: To provide a compound having an inhibitory activity for an androgen receptor. A tetrahydropyridopyrimidine compound represented by the following general formula (I) or a pharmaceutically acceptable thereof (in the formula, X and R are as defined in the specification).

Abstract: In an adjustment step, an adjustment purpose toner image is formed on an intermediate transfer belt, and the adjustment purpose toner image is removed from the intermediate transfer belt by a cleaning member contacting the intermediate transfer belt and through an electrostatic cleaning step. This adjustment step is executed in a state where a toner attachment amount on a charging member is switched from a first limit value, which is allowed in the image forming step to a second limit value, which is allowed immediately before executing the adjustment step. This switching is performed by the execution of a toner discharging step, where a power supply changes the state of applying voltage to the charging member from that in the electrostatic cleaning step, so that toner attached to the charging member is transferred to the intermediate transfer belt.

Abstract: An image forming apparatus includes a controller for forming an adjustment toner image in a region corresponding to between a first region corresponding to a preceding sheet and a second region corresponding to a subsequent sheet, wherein the controller selectively executes a first mode for setting as a first length a gap between the adjustment image and a trailing edge of the first region and for setting as a second length a gap between the adjustment toner image and a leading end of the second region, or a second mode for setting as a third length a gap between the adjustment toner image and the trailing edge of the first region and for setting as a fourth length a gap between the adjustment image and the leading end of the second region. The third is shorter than the first, and the fourth length is longer than the first length.

Abstract: Disclosed are compounds of the following formula and their pharmaceutically-acceptable salts, which have an effect of glucokinase activation and are useful in the field of medicines for treatment for diabetes, obesity, etc. (wherein ring A represents a pyrazolyl group optionally having a lower alkyl group, etc.; ring B represents a heteroaryl group; R represents a lower alkyl group, etc.; R1 represents a group of a formula: (wherein R11 and R12 each independently represent a hydrogen atom, etc.; m indicates an integer of from 2 to 6), etc.; R2 represents a lower alkyl group, etc.; r indicates an integer of from 0 to 3; k indicates an integer of from 0 to 4).

Abstract: Disclosed are compounds of the following formula and their pharmaceutically-acceptable salts, which have an effect of glucokinase activation and are useful in the field of medicines for treatment for diabetes, obesity, etc. (wherein ring A represents a pyrazolyl group optionally having a lower alkyl group, etc.; ring B represents a heteroaryl group; R represents a lower alkyl group, etc.; R1 represents a group of a formula: (wherein R11 and R12 each independently represent a hydrogen atom, etc.; m indicates an integer of from 2 to 6), etc.; R2 represents a lower alkyl group, etc.; r indicates an integer of from 0 to 3; k indicates an integer of from 0 to 4).

Abstract: The present invention relates to compounds, which are useful for treatment and/or prevention of diabetes mellitus, diabetes mellitus complications or obesity, since the compounds have glucokinase-activating effects, and are presented in Formula (I): wherein R1 represents a carbamoyl group; R2 represents a lower alkyl group; both of X1 and X2 represent CH, or any one of X1 and X2 represents a nitrogen atom and the other represents CH; a group of represents a group selected from the group consisting of a pyridinyl, a pyrazinyl, a pyrazolyl, a thiadiazolyl, a triazolyl, an isoxazolyl and a thiazolyl group; and k is zero or 1, or relates to pharmaceutically acceptable salts thereof.

Abstract: Compounds of a formula (I) and their pharmaceutically-acceptable salts are disclosed. The compounds have glucokinase-activating effect and are therefore useful for treatment of diabetes and obesity. R1 and R2 each independently represent a lower alkyl group; X1 represent a group of a formula (II-1): wherein: R11 and R12 each independently represent a hydrogen atom or a lower alkyl group, or taken together with the nitrogen atom to which they bond, R11 and R12 may form a 4- to 7-membered nitrogen-containing aliphatic ring (one carbon atom constituting the 4- to 7-membered nitrogen-containing aliphatic ring may be replaced by an oxygen atom), or taken together with a carbon atom in (CH2)m, R11 and R12 may form a 4- to 7-membered nitrogen-containing aliphatic ring; m indicates an integer of from 1 to 3.

Abstract: Disclosed are compounds of the following formula and their pharmaceutically-acceptable salts, which have an effect of glucokinase activation and are useful in the field of medicines for treatment for diabetes, obesity, etc. (wherein ring A represents a pyrazolyl group optionally having a lower alkyl group, etc.; ring B represents a heteroaryl group; R represents a lower alkyl group, etc.; R1 represents a group of a formula: (wherein R11 and R12 each independently represent a hydrogen atom, etc.; m indicates an integer of from 2 to 6), etc.; R2 represents a lower alkyl group, etc.; r indicates an integer of from 0 to 3; k indicates an integer of from 0 to 4).